Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis

    Clinical Journal of the American Society of Nephrology Date published:

  • The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

    Diabetes Date published:

  • 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

    Diabetes Date published:

  • P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published:

  • Maternal cardiovascular risk after hypertensive disorder of pregnancy

    Heart Date published:

  • Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis

    BMJ Date published:

  • Elastic Chest Compression Reduced Hyperinflation in People with Chronic Obstructive Pulmonary Disease

    D28. COPD: FROM PATHOGENESIS TO PROGNOSIS Date published:

  • Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor

    Heart, Lung and Circulation Date published:

  • A Novel Cardioprotective Therapy That Also Improves Glycemia

    JAMA Date published:

  • 1054-05 EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Date published:

  • EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China

    Circulation Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • ELASTIC CHEST COMPRESSION REDUCED HYPERINFLATION IN PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Date published: